Generic Name and Formulations:
Nitroglycerin 0.1mg/hr, 0.2mg/hr, 0.4mg/hr, 0.6mg/hr; transdermal patches.
Medicis Pharmaceuticals Corp
Indications for MINITRAN:
Prophylaxis of angina. Not for acute attacks.
Initially one 0.2mg/hr or 0.4mg/hr patch for 12–14hrs/day. Remove patch for 10–12hrs/day.
Acute or recent MI. Volume depletion. Hypotension. Heart failure. Hypertrophic cardiomyopathy. Reduce dose or discontinue if hypotension occurs. Remove before defibrillation or cardioversion. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Severe hypotension with sildenafil. Hypotension potentiated with alcohol, other vasodilators, calcium channel blockers.
Headache, dizziness, flushing, hypotension, increased angina, tachycardia, faintness, nausea, vomiting, rash.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Self-Predictions for Well-Being Influence Satisfaction After Mastectomy, Breast Reconstruction
- Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Gabapentin Improves Postoperative Opioid Cessation, But Not Pain Resolution
- Early Integration of Palliative Care Improves Quality of Life in Advanced Cancer
- Cisplatin-Induced Adverse Events in Osteosarcoma Not Improved With Pantoprazole
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Cachexia Not Improved With Celecoxib Plus Megestrol vs Megestrol Alone
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Efficacy and Safety of COX-2 Inhibitors for Advanced Non-small-cell Lung Cancer With Chemotherapy: A Meta-analysis
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|